Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 2/2016

01-04-2016 | Review Article

Adhesion molecules and the extracellular matrix as drug targets for glioma

Authors: Toshihiko Shimizu, Kazuhiko Kurozumi, Joji Ishida, Tomotsugu Ichikawa, Isao Date

Published in: Brain Tumor Pathology | Issue 2/2016

Login to get access

Abstract

The formation of tumor vasculature and cell invasion along white matter tracts have pivotal roles in the development and progression of glioma. A better understanding of the mechanisms of angiogenesis and invasion in glioma will aid the development of novel therapeutic strategies. The processes of angiogenesis and invasion cause the production of an array of adhesion molecules and extracellular matrix (ECM) components. This review focuses on the role of adhesion molecules and the ECM in malignant glioma. The results of clinical trials using drugs targeted against adhesion molecules and the ECM for glioma are also discussed.
Literature
1.
Penas-Prado M, Gilbert MR (2007) Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 7:641–661CrossRefPubMed
2.
Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A (2004) Angiogenesis and invasion in gliomas. Cancer Treat Res 117:263–284CrossRefPubMed
3.
Onishi M, Kurozumi K, Ichikawa T, Date I (2013) Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53:755–763CrossRef
4.
Kurozumi K, Onishi M, Ichikawa T et al (2013) III. Molecular targeting therapy for glioma-bevacizumab and cilengitide. Gan To Kagaku Ryoho 40:718–722PubMed
5.
6.
Varner JA, Cheresh DA (1996) Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69–87
7.
Wong ML, Prawira A, Kaye AH, Hovens CM (2009) Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 16:1119–1130CrossRefPubMed
8.
Onishi M, Ichikawa T, Kurozumi K, Date I (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28:13–24CrossRefPubMed
9.
Onishi M, Ichikawa T, Kurozumi K et al (2015) Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol 32:184–194CrossRefPubMed
10.
Rooprai HK, McCormick D (1997) Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17:4151–4162PubMed
11.
Gumbiner BM (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6:622–634CrossRefPubMed
12.
Nakada M, Nakada S, Demuth T, Tran N, Hoelzinger D, Berens M (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458–478CrossRefPubMed
13.
Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118–132CrossRefPubMed
14.
Huang Z-Y, Wu Y, Hedrick N, Gutmann DH (2003) T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21CIP1/WAF1 expression. Mol Cell Biol 23:566–578CrossRefPubMedPubMedCentral
15.
Osborn L, Hession C, Tizard R et al (1989) Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203–1211CrossRefPubMed
16.
Couldwell WT, de Tribolet N, Antel JP, Gauthier T, Kuppner MC (1992) Adhesion molecules and malignant gliomas: implications for tumorigenesis. J Neurosurg 76:782–791CrossRefPubMed
17.
Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987) The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 5:223–252CrossRefPubMed
18.
19.
Sasaki H, Yoshida K, Ikeda E et al (1998) Expression of the neural cell adhesion molecule in astrocytic tumors. Cancer 82:1921–1931CrossRefPubMed
20.
Owens GC, Orr EA, DeMasters BKK, Muschel RJ, Berens ME, Kruse CA (1998) Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58:2020–2028PubMed
21.
Prag S, Lepekhin EA, Kolkova K et al (2002) NCAM regulates cell motility. J Cell Sci 115:283–292PubMed
22.
Edvardsen K, Chen W, Rucklidge G, Walsh FS, Obrink B, Bock E (1993) Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases. Proc Natl Acad Sci 90:11463–11467CrossRefPubMedPubMedCentral
23.
Woodfin A, Voisin M-B, Nourshargh S (2007) PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27:2514–2523CrossRefPubMed
24.
25.
Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100CrossRefPubMed
26.
Bello L, Francolini M, Marthyn P et al (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49:380–389 (discussion 390) PubMed
27.
Schnell O, Krebs B, Wagner E et al (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18:378–386CrossRefPubMedPubMedCentral
28.
Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571CrossRefPubMed
29.
Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345–1362CrossRefPubMedPubMedCentral
30.
Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I (2012) Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52:539–547CrossRef
31.
Novak U, Kaye AH (2000) Extracellular matrix and the brain: components and function. J Clin Neurosci 7:280–290CrossRefPubMed
32.
33.
34.
Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4:188–199CrossRef
35.
Sweeney SM, Orgel JP, Fertala A et al (2008) Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J Biol Chem 283:21187–21197CrossRefPubMedPubMedCentral
36.
Canty EG, Kadler KE (2005) Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 118:1341–1353CrossRefPubMed
37.
38.
39.
Ogawa K, Oguchi M, Nakashima Y, Yamabe H (1989) Distribution of collagen type IV in brain tumors: an immunohistochemical study. J Neurooncol 7:357–366CrossRefPubMed
40.
Senner V, Ratzinger S, Mertsch S, Grässel S, Paulus W (2008) Collagen XVI expression is upregulated in glioblastomas and promotes tumor cell adhesion. FEBS Lett 582:3293–3300CrossRefPubMed
41.
Bauer R, Ratzinger S, Wales L et al (2011) Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem 27:217–226CrossRefPubMed
42.
Rutka JT, Apodaca G, Stern R, Rosenblum M (1988) The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69:155–170CrossRefPubMed
43.
Giese A, Rief MD, Loo MA, Berens ME (1994) Determinants of human astrocytoma migration. Cancer Res 54:3897–3904PubMed
44.
Deryugina EI, Bourdon MA (1996) Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109:643–652PubMed
45.
Zagzag D, Friedlander DR, Dosik J et al (1996) Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182–189PubMed
46.
Zagzag D, Shiff B, Jallo GI et al (2002) Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 62:2660–2668PubMed
47.
Mahesparan R, Read T-A, Lund-Johansen M, Skaftnesmo K, Bjerkvig R, Engebraaten O (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105:49–57PubMed
48.
49.
Nishimori H, Shiratsuchi T, Urano T et al (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15:2145–2150CrossRefPubMed
50.
Nakada M, Nakamura H, Ikeda E et al (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154:417–428CrossRefPubMedPubMedCentral
51.
Duda D, Sunamura M, Lozonschi L et al (2002) Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 86:490–496CrossRefPubMedPubMedCentral
52.
Kudo S, Konda R, Obara W et al (2007) Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 18:785–791PubMed
53.
Kaur B, Brat DJ, Devi NS, Van Meir EG (2005) Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24:3632–3642CrossRefPubMed
54.
Kaur B, Cork SM, Sandberg EM et al (2009) Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 69:1212–1220CrossRefPubMedPubMedCentral
55.
Hardcastle J, Kurozumi K, Dmitrieva N et al (2010) Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18:285–294CrossRefPubMedPubMedCentral
56.
Yoo JY, Haseley A, Bratasz A et al (2012) Antitumor efficacy of 34.5 ENVE: a transcriptionally retargeted and “Vstat120”-expressing oncolytic virus. Mol Ther 20:287–297CrossRefPubMedPubMedCentral
57.
Kurozumi K, Hardcastle J, Thakur R et al (2008) Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16:1382–1391CrossRefPubMedPubMedCentral
58.
Kurozumi K, Hardcastle J, Thakur R et al (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99:1768–1781CrossRefPubMed
59.
Fujii K, Kurozumi K, Ichikawa T et al (2013) The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20:437–444CrossRefPubMed
60.
Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810CrossRefPubMed
61.
Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG (2015) Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review). Int J Mol Med 36:1451–1463PubMedPubMedCentral
62.
Ishida J, Kurozumi K, Ichikawa T et al (2015) Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma. Brain Tumor Pathol 32:245–252CrossRefPubMed
63.
64.
Kireeva ML, Lam SC, Lau LF (1998) Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 273:3090–3096CrossRefPubMed
65.
Iozzo RV, Schaefer L (2015) Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol 42:11–55CrossRefPubMed
66.
Wu YJ, La Pierre DP, Jin W, Albert JY, Burton BY (2005) The interaction of versican with its binding partners. Cell research 15:483–494CrossRefPubMed
67.
Silver DJ, Siebzehnrubl FA, Schildts MJ et al (2013) Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 33:15603–15617CrossRefPubMedPubMedCentral
68.
Hu F, a Dzaye OD, Hahn A et al (2015) Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol 17:200–210CrossRefPubMedPubMedCentral
69.
Heckmann D, Kessler H (2007) Design and chemical synthesis of integrin ligands. Methods Enzymol 426:463–503CrossRefPubMed
70.
Meyer A, Auernheimer J, Modlinger A, Kessler H (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 12:2723–2747CrossRefPubMed
71.
Tabatabai G, Weller M, Nabors B et al (2010) Targeting integrins in malignant glioma. Target Oncol 5:175–181CrossRefPubMed
72.
Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA (1992) Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117:1101–1107CrossRefPubMed
73.
MacDonald TJ, Stewart CF, Kocak M et al (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924CrossRefPubMed
74.
MacDonald TJ, Taga T, Shimada H et al (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151–157PubMed
75.
76.
Brooks PC, Montgomery AM, Rosenfeld M et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164CrossRefPubMed
77.
Onishi M, Ichikawa T, Kurozumi K et al (2013) Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 33:162–174CrossRefPubMed
78.
Tate MC, Aghi MK (2009) Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6:447–457CrossRefPubMed
79.
Ishida J, Onishi M, Kurozumi K et al (2014) Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol 7(292–302):e291
80.
Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263–4272PubMed
81.
Abdollahi A, Griggs DW, Zieher H et al (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270–6279CrossRefPubMed
82.
Tentori L, Dorio AS, Muzi A et al (2008) The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19:1039–1043PubMed
83.
Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617CrossRefPubMed
84.
Mikkelsen T, Brodie C, Finniss S et al (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124:2719–2727CrossRefPubMed
85.
Shimazu Y, Kurozumi K, Ichikawa T et al (2015) Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene Ther 22:146–154CrossRefPubMed
86.
Eskens FA, Dumez H, Hoekstra R et al (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917–926CrossRefPubMed
87.
Stupp R, Van Den Bent M, Erridge S, et al. (2010) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). ASCO Annual Meeting Proceedings. p TPS152
88.
Nabors LB, Fink KL, Mikkelsen T et al (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17:708–717CrossRefPubMed
89.
Weller M, Nabors L, Gorlia T et al (2016) Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget. [Epub ahead of print]
90.
Mason WP (2015) End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro Oncol 17:634–635CrossRefPubMed
91.
92.
Hansen JM, Harris C (2004) A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-κB pathway. Antioxid Redox Signal 6:1–14CrossRefPubMed
93.
Fine HA, Figg WD, Jaeckle K et al. (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708–715PubMed
94.
Giglio P, Dhamne M, Hess KR et al (2012) Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118:3599–3606CrossRefPubMed
95.
Bigner DD, Brown M, Coleman RE et al (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′) 2-a preliminary report. J Neurooncol 24:109–122CrossRefPubMed
96.
Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397CrossRefPubMed
97.
Reulen H-J, Poepperl G, Goetz C et al (2015) Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. J Neurosurg 123:760–770CrossRefPubMed
98.
Metadata
Title
Adhesion molecules and the extracellular matrix as drug targets for glioma
Authors
Toshihiko Shimizu
Kazuhiko Kurozumi
Joji Ishida
Tomotsugu Ichikawa
Isao Date
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Brain Tumor Pathology / Issue 2/2016
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-016-0261-9

Other articles of this Issue 2/2016

Brain Tumor Pathology 2/2016 Go to the issue

Case Report

A mixed choroid plexus papilloma and ependymoma

Review Article

Blood–brain barrier and blood–cerebrospinal fluid barrier in normal and pathological conditions

Original Article

Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma

Original Article

Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors

Case Report

‘Papillary’ solitary fibrous tumor/hemangiopericytoma with nuclear STAT6 expression and NAB2-STAT6 fusion

Original Article

Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas